Posted on Leave a comment

Medical Gas Market Size & Share | Global Industry Report, 2014-2024

The global medical gas market size was valued at USD 7.5 billion in 2016 and is expected to witness a CAGR of 9.0% during the forecast period. Rising incidence of chronic diseases, growing number of industry-friendly safety initiatives undertaken by the government, implementation of U.S. FDA safety and innovation act, growing base of geriatric population, and increasing demand for home Health care and point of care products are some of the major factors propelling the growth of the medical gases market. 

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Medical gases are labeled as medical products and subsequently the related equipment are termed as medical devices. They are frequently used by Health care professionals for diagnostic and treatment purposes. Additionally, it has varied usage in pharmaceutical and biotechnology industry, such as, pharmaceutical manufacturing, cell culture studies, and drug discovery and development.

Chronic diseases such as asthma, diabetes, cancer, respiratory diseases, cardiovascular diseases, and other non-communicable disease have become a global burden, crippling nations. According to the Centers for Disease Control and Prevention, 1 out of 2 adults in the U.S. suffers from a chronic disease and 1 in 4 adults suffer from more than two chronic diseases.

Data from the same source indicate that 86% of the national Health care expenditure amounting to 2.7 trillion USD were spent on the treatment of chronic and mental health conditions in the U.S. According to American Public Health Association, seven out of ten deaths in the U.S. is a result of chronic disease. These facts are indicative of the alarming rise in chronic diseases which is expected to fuel the market growth of medical gases as they are used very commonly in diagnostic and therapeutic settings.

In addition, increasing geriatric population susceptible to chronic conditions is also expected to boost demand for technologically advanced equipment that aid in the management and treatment of various such conditions. Old age heightens the need for Health care by making individuals more susceptible to diseases especially pertaining to the respiratory system thus triggering patient hospitalization rates. Statistics suggest that 55% – 60% of patients admitted in hospitals are administered with medical gases. Thus, with a rise in geriatric population globally, the demand for medical gases is expected to rise considerably.

Growing demand for home healthcare and point of care markets is expected to boost the medical gases and equipment market by triggering a rise in demand for packaged medical grade gases (such as oxygen). In July, 2012, the U.S. Congress passed a bill putting into effect the Food and Drug Safety and Innovation Act. This act is expected to serve this market as a driver during the forecast period owing to elimination of drug user fees for medical gas manufacturers and establishment of a standard certification process for medical gas and equipment products among others.

Application Insights

Based on application, the market is segmented into therapeutic, diagnostic, and others. The other applications taken into consideration are pharmaceutical manufacturing, biotechnology, and other research activities. The therapeutic application held the largest market revenue in 2016 owing to a broad range of medical gases used to treat and manage various disease conditions. Medical gases used for diagnostics are also expected to gain a lucrative market share with the highest CAGR of 10% during the forecast period.

Medical gases are needed to standardize and maintain medical devices used for the delivery of anesthetic gases. They are usually used for patient diagnostics such as blood gas analysis and lung function testing. For instance, liquid helium is required in MRI to cool down superconductive magnets coil scanners. Thus, varied usage of these gases is expected to propel their market growth.

Equipment Insights

Medical gas equipment involves various types of products including manifolds, vacuum systems, alarm systems, flowmeters, medical air compressors, cylinders, hose assemblies and valves, outlets, regulators and masks. Medical gas vacuum systems are used to provide safe and sufficient flows at desired pressure levels to the medical gas outlets or vacuum inlet terminals. This product held the largest share in 2016 and is expected to continue to maintain its dominancy throughout the forecast period owing to its rapidly increasing penetration rates and relatively higher prices.

Masks showcased the highest CAGR of 10.9% during the forecast period owing to its frequent usage for medical gas administration. Since medical gas outlets play an important role in the distribution of medical gases, they are also expected to gain a lucrative market share in the near future. Medical air compressors which are mechanical devices that store air by compression and later used in air driven medical equipment such as dental tools, ventilators and nebulizers are also expected to gain a significant share in the market.

Regional Insights

The key regions considered in the medical gases market are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The U.S. is the estimated to dominate the overall market with the largest market share. In addition, the increasing geriatric population along with increasing prevalence of chronic diseases is expected to further enhance the sector growth in the North American region.

The European region followed closely after the North American region in terms of market share.  Some of the major factors attributing to the growth of this region is the presence of various associations such as the EIGA (European Industrial Gases Association) and MGA (Medical Gas Association) which aid in providing standard rules and regulations for medical gas manufacturers.

On the other hand, Asia Pacific is anticipated to be the fastest growing segment, owing to densely populated nations such as China and India and an increase in Health care spending in the respective nations.

Medical Gases Market Share Insights

The major players leading the market are The Linde Group; Airgas, Inc.; BeaconMedaes; Medical Gas Solutions Ltd.; Air Products and Chemicals; Praxair, Inc.; Air Liquide; and Matheson Tri-Gas among others. The medical gases market is highly fragmented with many local and few global players.

Key strategies adopted by the major players, such as collaborations, acquisitions and mergers, new product launches are estimated to fuel the market growth of the companies and subsequently the market. Strategies such as these aids companies in strengthening their global existence for long-term sustained growth in the industry. For instance, in June 2015, Air Liquide announced acquisition of Baywater Health care Ireland Ltd, to expand its home Health care business in Europe. This acquisition is expected father add to the company’s existing product portfolio allowing it to deliver more to their clients. Various collaborations are also expected to benefit the market players in strengthening their position in the market. For instance, in July 2016, Praxair expands its Helium supply in Central Europe by signing a long-term agreement for the purchase of helium (liquid) from PGNiG, the only producer of helium in Central Europe.

Report Scope

Attribute

Details

Base year for estimation

2015

Actual estimates/Historical data

2012 – 2015

Forecast period

2016 – 2024

Market representation                                   

Revenue in USD Million and CAGR from 2016 to 2024

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, UK, Germany, India, China, Brazil, Mexico, South Africa

Report coverage        

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global medical gases market report on the basis of gas type equipment, application, and region:

  • Gas Type Outlook (Revenue, USD Million, 2013 – 2024)

    • Pure Gases

      • Medical Air

      • Carbon Dioxide

      • Oxygen

      • Nitrogen

      • Nitrous Oxide

      • Helium

    • Gas Mixtures

      • Carbon Dioxide Oxygen Mixtures

      • Oxygen-Nitrous Oxide Mixtures

      • Ethylene Oxide

      • Oxyfume 2000

      • Helium Oxygen Mixtures

      • Aerobic Mixtures

      • Anaerobic Mixtures

      • Blood Gas Mixtures

      • Laser Gas Mixtures

      • Lung Mixtures

  • Equipment Outlook (Revenue, USD Million, 2013 – 2024)

    • Manifolds

    • Vacuum Systems

    • Alarm Systems

    • Flowmeters

    • Medical Air Compressors

    • Cylinders

    • Hose Assemblies and Valves

    • Outlets

    • Regulators

    • Masks

  • Application Outlook (Revenue, USD Million, 2013 – 2024)

    • Therapeutic

    • Diagnostic

    • Others

  • Regional Outlook (Revenue, USD Million, 2013 – 2024)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

    • Asia Pacific

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • The Middle East and Africa

      • South Africa

HOW D’OXYVA CAN HELP?

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation. It’s platform solution uses vaporized ultra-purified carbon dioxide that acts as a catalyst for the body to help improve its functions and heal itself.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Hydroxychloroquine Fails to Help Coronavirus Patients in Largest Study of the Drug to Date

In a study published in the New England Journal of Medicine, scientists led by a team at Columbia University found that people infected with COVID-19 taking hydroxychloroquine do not fare better than those not receiving the drug.

The study published Thursday is the largest to date to investigate the drug, which is approved by the U.S. Food and Drug Administration to treat malaria and certain autoimmune disorders, as a treatment for COVID-19. Dr. Neil Schulger, chief of the division of pulmonary, allergy and critical care medicine at Columbia, and his team studied more than 1,300 patients admitted to New York-Presbyterian Hospital-Columbia University Irving Medical Center for COVID-19.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Some received hydroxychloroquine on an off-label basis, a practice that allows doctors to prescribe a drug that has been approved for one disease to treat another — in this case, COVID-19. About 60% of the patients received hydroxychloroquine for about five days. They did not show any lower rate of needing ventilators or a lower risk of dying during the study period compared to people not getting the drug.

 

“We don’t think at this point, given the totality of evidence, that it is reasonable to routinely give this drug to patients,” says Schluger. “We don’t see the rationale for doing that.” While the study did not randomly assign people to receive the drug or placebo and compare their outcomes, the large number of patients involved suggests the findings are solid.

Based on the results, Schluger says doctors at his hospital have already changed their advice about using hydroxychloroquine to treat COVID-19. “Our guidance early on had suggested giving hydroxychloroquine to hospitalized patients, and we updated that guidance to remove that suggestion,” he says.

The original support of hydroxychloroquine came largely from a small study conducted in France that suggested people receiving the drug did better than those not getting it. In the U.S., President Trump also expressed interest in the drug as a possible way to control the growing pandemic. However, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and member of Trump’s White House Coronavirus Task Force, urged caution and recommended more rigorous studies and data on the drug’s effect on COVID-19.

Still, Schluger says the urgent need to help patients in the middle of a pandemic led many doctors and hospitals to latch on to hydroxychloroquine as a potentially effective therapy. “Physicians see patients who are dying at an unbelievable rate, and want to do something to try to help them,” he says. “But I think the history of medicine shows us that some hunches are right and many, many, many of them are wrong.” In a survey conducted by health care polling company Sermo, 55% of physicians around the world who were surveyed reported using hydroxychloroquine. Only 29%, however, rated it as highly safe — the drug is linked to higher risk of abnormal heart rhythms.

The results of the current study are likely to change how doctors treat hospitalized patients who are severely ill. But Schluger says it’s still possible that hydroxychloroquine can play a role in controlling COVID-19, perhaps as a way to prevent infection among people who are at high risk of getting exposed to the virus, such as health care workers. Other studies are investigating that possibility.

“It’s really important for us to know which treatments work, and which do not, so patients should be offered the chance to be in a clinical trial,” says Schluger. “It’s probably the best thing they can do for themselves and for society as a whole, so we can get answers really quickly to identify the treatments that work and discard the treatments that don’t work.”

HOW D’OXYVA CAN HELP?

Our organization has been on the forefront in the fight against the novel coronavirus that originated in Wuhan, China (Covid-19) since January of this year due to our organization’s operations in major countries across Asia. We all should understand the need to act now and arrest this crisis head on by spurring economic activity wherever we can and providing effective, affordable and rapid testing and treatments for the masses.

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Why the World’s Highest Virus Death Rate Is in Europe’s Capital

In an art-deco building in the heart of Brussels, Belgium’s leading scientists gather daily to announce the country’s coronavirus toll. It’s been grim reading.

Despite having only 11 million people, the country has reported more deaths from the disease than China. With some 57 fatalities per 100,000 inhabitants, it has the highest per-capita death rate in the world — almost four times that of the U.S.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Belgian Toll

Europe’s highest coronavirus death rates are in tiny Belgium

 

Source: ECDC, data as of April 24

According to Belgian officials, the reason for the grisly figures isn’t overwhelmed hospitals — 43% of intensive-care beds were vacant even at the peak of the crisis — but the country’s bureaucratic rigor.

Unlike many other countries, the home of the European Union’s top institutions counts deaths at nursing homes even if there wasn’t a confirmed infection.

“We often get criticism — oh, you’re making Belgium look bad — we think it’s the opposite,” Steven Van Gucht, head of the viral disease division at the Sciensano public-health institute, said while maintaining the requisite distance of 1.5 meters (5 feet). “If you want to compare our numbers with a lot of other countries, you basically have to cut them in half.”

Clearer Picture

About 95% of Covid-19 deaths in elderly care homes haven’t been diagnosed, yet Belgium makes the decision to register them based on the symptoms shown and who the people have been in contact with. The goal is to get a clearer picture of the outbreak and better target hot spots.

At the start of each briefing at the Residence Palais, a stone’s throw from the European Commission, Belgian officials detail the day’s statistics in French and Dutch. They draw particular attention to those who die outside of hospitals — typically around half the total.

The impact of the disease on vulnerable care-home residents is a growing issue. While Europe knew it would need more ventilators and intensive-care capacity once the virus spread beyond China, the impact on nursing homes was unexpected, according to Agoritsa Baka, a senior expert at the European Centre for Disease Prevention and Control.

“It’s a disaster,” she said. “We did not realize how devastating Covid would be if it entered these populations.”

Excess Mortality

Yet not all European countries are measuring the impact in the same way, meaning that the numbers of coronavirus deaths are likely thousands higher than the official count of more than 110,000.

The consequence of uneven practices was evident in France. When the country reported data from some nursing homes for the first time in early April, those fatalities were almost double the number of people that died in hospitals.

Last week, Spain had to adjust its historical data after Catalonia started including people who had symptoms but didn’t test positive. This week a local radio broadcaster reported that more than 6,800 elderly died in Spanish nursing homes with symptoms but weren’t recorded in official data.

Germany’s unusually low mortality rate may be helped by the fact that the country only counts deaths that have a positive virus test.

Such discrepancies show up in a concept called “excess mortality,” the number of extra fatalities above typical trends. In Belgium, just over 300 people normally die every day, but this year, it’s jumped to nearly 600.

A project called euroMOMO, originally developed for gauging the scale of flu epidemics, is now being used to track the impact of the coronavirus in Europe.

Good Surveillance

Belgium’s practice means that nearly all deaths are accounted for in a given week, while neighboring Netherlands has around 1,000 undefined fatalities. Some countries’ virus deaths are around a sixth of their excess mortality rates.

Better tracking could help improve Europe’s response to outbreaks, especially as the region gradually eases lockdown restrictions, raising the prospect of second-wave outbreaks. Coordinated procedures could also defuse tensions as Europe grapples with recovery efforts.

“We are still in a situation where within the EU we do not count the same way, which could lead to political misunderstandings,” said Pascal Canfin, chair of EU Parliament’s environment and health committee. “It leads to different perception awareness of the crisis.”

In the meantime, the world’s eyes shouldn’t be focused on Belgium because at least the extent of the problem is known, according to Van Gucht.

“When you have a good surveillance system, you report a lot of cases,” he said. “It’s the countries that are not reporting or that are reporting very low numbers, you should be more worried about.”

HOW D’OXYVA CAN HELP?

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Our organization has been on the forefront in the fight against the novel coronavirus that originated in Wuhan, China (Covid-19) since January of this year due to our organization’s operations in major countries across Asia. We all should understand the need to act now and arrest this crisis head on by spurring economic activity wherever we can and providing effective, affordable and rapid testing and treatments for the masses.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

New COVID-19 Clinical Trial Announced To Treat Over 90% of Patients With Underlying Medical Conditions

A new clinical trial is being announced today that could significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives! Circularity Healthcare’s trial will help some of the most at-risk patients suffering from complications due to diabetes, poor circulation, hypertension, cardiovascular disease and high blood pressure. The trial will involve the use of Circularity’s already FDA-approved drug and IDE device D’OXYVA® (deoxyhemoglobin vasodilator) – a non-toxic, non-invasive microcirculation transdermal device.  It is the first biotech solution of its kind to improve overall oxygen-rich blood flow. The device has been shown to significantly heal diabetic wounds, reduce the risks of amputations, prevent sepsis and septic shock,  improve blood pressure and general vital organ function of the pancreas, liver, brain and kidneys, while increasing overall health for some of the most vulnerable patients. 

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“Anyone who suffers from an underlying condition should know that this proven treatment option is available,” says Circularity Healthcare CEO Norbert Kiss. “Every medical report released so far shows that severe COVID-19 patients need blood oxygenation and blood thinners. The overwhelming majority of patients have diabetes and cardiovascular issues beyond pulmonary complications and they all have sepsis setting in early on. These are the exact main vitals and chronic diseases D’OXYVA improves like no other medication currently available on the market.”

The recommendation for this new treatment is based on the following:

  • After eight years of three dozen human studies with leading experts at some of the most prestigious universities and hospitals in the world (including Penn State and Airlangga University), zero adverse effects were reported. D’OXYVA is currently expanding its Phase 3 trial with Professor David G. Armstrong and his colleagues.
  • The pharmaceutical-grade CO2 utilized by the D’OXYVA device has already been approved by the FDA (it is the same CO2 drug already readily available in every hospital and provided by the same supplier). There is just a 1-2 week IRB approval to launch the trials at any location due to the investigational device exemption (IDE) status of D’OXYVA. Additionally, with the device factory S.-based in Fremont, CA, all the regulated products are also readily-available to launch the trial.
  • The effects of transdermal CO2 have been widely noted in wound care as demonstrated in clinical studies. Healing, closure, prevention against sepsis and septic shock and recovery of an ulcer (non-healing) due to diabetes and cardiovascular complications are much faster and often successful where other modalities have failed.
  • All research projects performed up to date have consistently recorded a significant decrease in systolic blood pressure (from the heart) and diastolic (return to the heart) blood pressure. These results have been consistent throughout all study time periods   up to 240 minutes (the longest time period evaluated after treatment).
  • Systemically, CO2 therapy has shown great success to improve the healthcare of patients with high blood pressure, general vital organ function of patients with high blood pressure, and general vital organ function like that of the pancreas, liver, brain, and kidneys

The clinical trials are now waiting IRB approvals and are about to launch under existing contracts at multiple sites including top U.S. universities such as Harvard, Yale, M.I.T, USC, and UCLA, with more physicians and patients being invited to participate. Since the product can be monitored at home, potential patients do not have to be currently admitted to a hospital in order to take part in the trial. For more information on the trial or to sign up, please visit https://doxyva.com/covid-19/ or call 626.240.0956.

About Circularity Healthcare, LLC
Circularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed.

For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)circularityhealthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956.

Forward-Looking Information
This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Join Professional Fitness Icon Eva Marie in a 30-Day D’OXYVA Challenge

Former professional wrestler, actress, and fitness model Eva Marie recently announced a 30-day challenge based on a daily application of D’OXYVA. In a five-minute video on her Instagram page, she and her husband announced that they would both be testing the product to determine the impact on their health and vitality. Marie and the makers of D’OXYVA are also hosting a contest in which her followers can enter to win their own 30-day challenge package.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Having been an athlete most of her life, Eva Marie has always been a natural fitness enthusiast. After winning the 2012 Powertech Model competition, she joined the WWE in May 2013. Through her time as a wrestler, manager, and actor with the Total Divas, she has always strived for maximum fitness. In recent years, she and her husband have launched social media channels focusing on fashion and fitness and helmed a number of entrepreneurial enterprises, including the Natalie Eva Marie X Ryderwear fashion collection and NEM Fit workout program.

30-Day D’OXYVA Challenge

In part because of the COVID-19 pandemic, Eva Marie and her husband decided to spend their physical distancing time experimenting with various health and wellness programs. Beginning April 17, 2020, the couple decided to use D’OXYVA for the next thirty days and report the results to her fans. To better understand the impact, they will take a few baseline health measurements, such as blood oxygen levels. After the challenge, they will take more measurements to provide anecdotal and statistical comparisons. The video also demonstrates the non-invasive application of the D’OXYVA product.

Why D’OXYVA?

D’OXYVA is a revolutionary new application providing a number of powerful health benefits. At its core, the five-minute, noninvasive application exposes the body to a painless vapor of purified CO2 molecules across the skin. The body responds to this exposure by increasing circulation to the affected areas. Improvements in microcirculation have been proven to lead to a number of positive health outcomes, including greater healing and immune responses.

D’OXYVA has been shown to eliminate nearly all spider and varicose vein markings and speed the healing of open wounds. Improvements in blood flow and nerve stimulation can relieve chronic pain from conditions such as neuropathy or advanced diabetes. As an added benefit, D’OXYVA is a single product that can replace a number of treatments for various conditions. Users can save money and time by consolidating therapies into one application.

Benefits for Healthy People

D’OXYVA is not just for people suffering from chronic conditions. Daily use of D’OXYVA can also provide improvements in circulation and potentially produce benefits related to general fitness, cardiovascular efficiency, and endurance. Eva Marie’s 30-day challenge is intended to allow her to experience and chart these results for the general public, and Marie and the makers of D’OXYVA want to share these benefits with you!

Two lucky people will receive a complete month’s supply of D’OXYVA, including cartridges and the oximeter, to measure blood oxygen levels. Winners will be chosen at random on Monday, April 20, 2020. To enter your name:

 

For More Information:

Don’t wait to join Eva Marie in her 30-day challenge of D’OXYVA! Even if you don’t win, visit https://doxyva.com/shop/ today for great deals on equipment and supplies. You can find sales of up to 35% off for a limited time only!

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Non-Invasive Microcirculatory Device Could Help COVID-19 Patients With Underlying Medical Conditions

covid 19

Read article in PRWeb

According to the CDC, nearly 90% of Americans being hospitalized with COVID-19 have an underlying medical condition. Healthcare technology company Circularity Healthcare, creators of D’OXYVA®, is looking to help these patients treat those conditions faster to better their chances of recovery. D’OXYVA® (deoxyhemoglobin vasodilator), the first biotech solution of its kind, provides non-invasive, transdermal microcirculation to improve overall oxygen-rich blood flow – an effective treatment option for a variety of conditions including diabetes, hypertension, cardiovascular issues, COPD, and high blood pressure.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“D’OXYVA is aimed at helping millions of people improve their health and their immune response,” says Circularity Healthcare CEO Norbert Kiss. “We are confident this device can save lives in the fight against the Coronavirus by helping repair the body’s functions in people with underlying conditions.” D’OXYVA speeds up the body’s healing process by improving micro and macro circulation and the autonomic nervous system (ANS), detoxifying the liver and kidney, reducing inflammation, and increasing oxygenation and delivery of nutrients. It is the only clinically-tested, non-invasive, portable, transdermal microcirculatory regenerative solution device.

The over-the-counter product is intended to ease the expense and inconvenience of time-consuming doctor visits by offering affordable and effective management of conditions that can take place in the comfort of your own home. “This is truly the future of optimized healthcare,” says Kiss. “D’OXVYA provides an advanced technology that offers a painless solution to help people manage chronic health conditions and see measurable results within a matter of weeks. This is a great way to save time and money by reducing the reliance on opioids and other expensive medications and office visits.”

Extensive clinical research conducted over an eight-year period has already shown incredible success rates. Trials have included over three dozen human clinical studies including double-blind, randomized, and placebo-controlled studies at Pennsylvania State University. The company is now significantly expanding Phase 3 human clinical trials working with the top ten universities in the U.S. targeting underlying conditions specific to COVID-19 risk factors such as oxygen-rich microcirculation in lungs, the heart, kidneys and other vital organs as well as inflammatory markers.

The science used to create the device received a 2019 Nobel Prize in Physiology Medicine. D’OXYVA works by utilizing FDA-cleared, non-toxic molecules (over-the-skin deoxyhemoglobin vasodilator) that deliver a vapor of pharmaceutical-grade CO2 and water to the peripheral microcirculation. This vapor is delivered through the placement of the D’OXYVA device over the thumb for a 5-minute period. The CO2 then travels into the microcirculation of the skin, where it causes a vasodilation that leads to increased perfusion. Since its introduction in 2012, the physician-recommended, easy-to-use device has helped users track and regain their health by repairing or growing new vessels and significantly improving nerve activities in the body.

“The fact is that D’OXYVA increases the effectiveness of the Microcirculatory System,” says Dr. Jim Bledsoe, PHD and Holistic Practitioner. “Increasing the blood flow will help the body improve itself.”

D’OXYVA is currently available OTC online.

The company is actively accepting donation requests from nurses and doctors to provide D’OXYVA for immediate lifesaving treatment of hospital patients in critical condition due to its Investigational Device Exemption (IDE) status under FDA regulations. For more information, please visit doxyva.com/covid-19 or call 626.817.6698.

About Circularity Healthcare, LLC Circularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed. For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)Circularity Healthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956. Forward-Looking Information This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.
Posted on Leave a comment

Nearly 90% of People Hospitalized for COVID-19 Have Underlying Conditions, Says CDC

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

For weeks, the world has been inundated with information about the COVID-19 pandemic. While cases continue to rise and researchers learn more about the novel coronavirus (SARS-CoV-2), most data has lacked a certain specificity needed to ensure that people take this illness seriously. But on Tuesday, the Centers for Disease Control and Prevention (CDC) was able to give a closer look at exactly who is most affected by COVID-19—and its findings underscore the importance of the preventive measures we’ve all been taking.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

In a new study published for the CDC’s Morbidity and Mortality Weekly Report, researchers found that the majority of those hospitalized due to COVID-19 have preexisting conditions—about 90% of patients, or nearly all, had one or more underlying conditions. The most common, per the CDC, include hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%).

The data collected for the study came from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), created for population-based surveillance for all confirmed COVID-19–related hospitalizations in the US. The CDC’s new study used the demographics of 1,482 COVID-19 patients admitted between March 1 and March 30, from across 14 different states: California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

Age also played a role in the hospitalization rates of COVID-19 patients—the study found that 74.5% of those hospitalized due to coronavirus were age 50 or older, with the highest rates among those over 65. Men were also disproportionately affected (54.4% of those hospitalized from COVID-19 were male), as were African Americans, who represented 33% of hospitalizations, despite only making up 18% of the total population studied.

The study points out that most of the underlying conditions among hospitalized COVID-19 patients are similar to those that affect hospitalized influenza patients, though those with COVID-19 are reportedly hospitalized at a higher rate. (According to data from the 2014-2015 through 2018-2019 flu seasons, 29-31% of hospitalized patients had chronic lung disease, versus 34.6% of COVID-19 patients with lung disease.)

But this isn’t the first set of data on the prevalence of underlying conditions among those hospitalized with COVID-19. In a previous Morbidity and Mortality Weekly Report published by the CDC on April 3, it was reported that, among 457 ICU hospital admissions and 1,037 non-ICU hospitalizations, 78% and 71% respectively occurred in those with one or more reported underlying health conditions. Another Chinese study published in the New England Journal of Medicine found that, of 1,099 hospitalized patients, coexisting illnesses were more common among those with severe disease (38.7%) versus non-severe disease (21%).

While this research is still preliminary and only accounts for about 10% of the entire US population, researchers maintain that these findings “underscore the importance of preventive measures” like social distancing, regular handwashing, and now, wearing face masks in public settings, in order to continue protecting older adults and those with underlying medical conditions from COVID-19.

The CDC also says that those with underlying health conditions who also have symptoms of COVID-19—including cough, fever, or shortness of breath, among others–should immediately contact their health care provider.

HOW D’OXYVA CAN HELP?

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

New CDC data shows danger of coronavirus for those with diabetes, heart or lung disease, other chronic conditions

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

People who have chronic medical conditions, such as diabetes, lung disease and heart disease, face an increased chance of being hospitalized with covid-19 and put into intensive care, according to data released Tuesday by the Centers for Disease Control and Prevention that is consistent with reports from China and Italy.

Share this:

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

The new data gives the most sweeping look at the way covid-19 is causing serious illnesses among people in the United States who already face medical challenges.

The report reinforces a critically important lesson: Although the disease is typically more severe among older people, people of any age with underlying medical conditions are at increased risk if they contract the virus, for which there is no vaccine or approved drug treatment. 

The CDC data is an initial description of how the disease appears to be affecting people who are already dealing with health challenges. The study did not break down the disease demographically, for example by age, sex, race or income. The agency also notes that this is essentially a snapshot and can’t capture the ultimate outcome for people who have been infected with the virus and haven’t yet recovered.

The report shows covid-19 is thrusting vulnerable people in the United States into intensive care units and disproportionately taking the lives of people who already face medical challenges.

The CDC analyzed more than 7,000 confirmed covid-19 cases across the country in which health officials had a written record about the presence or absence of any underlying medical condition. The preexisting conditions covered in the records include heart and lung diseases, diabetes, chronic renal disease, chronic liver disease, immunocompromised conditions, neurological disorders, neurodevelopmental or intellectual disability, pregnancy, current or former smoker status, and “other chronic disease.”

The CDC found that, of people requiring admission to an intensive care unit, 78 percent had at least one underlying health condition. Of people hospitalized but not requiring ICU admission, 71 percent had at least one such condition, compared with just 27 percent of people who didn’t need to be hospitalized.

Among all the cases analyzed, 10.9 percent of patients had diabetes mellitus, 9.2 had chronic lung disease and 9 percent had cardiovascular disease.

The report did not reach any conclusion about whether the severity of an underlying condition correlated to a more severe covid-19 illness.

Of the 7,160 patients whose chronic illness status was known through health records, 184 died, and 173 of them had an underlying condition, the CDC said. None of the deaths were among people under age 19.

Covid-19 is a respiratory disease. The virus typically infects the upper respiratory tract, but it can also venture deeper into the lungs and in some patients results in pneumonia-like symptoms, requiring hospitalization and sometimes intubation on a ventilator. People who smoke or have chronic lung conditions are especially vulnerable.

Diabetes and heart disease are similarly worrisome. Someone already suffering from heart problems — whether they had previous heart attack or required a stent installed because of plaque buildup in their vascular system — may have a heart that cannot take as much strain as the average person, said Amesh Adalja, an infectious disease physician at Johns Hopkins Center for Health Security.

When a patient gets infected with something like this coronavirus, the fever causes a spike in the heart rate. Shortness of breath means the patient gets less oxygen. People with limited cardiac capacity can go into arrest.

Diabetes is a metabolic syndrome that involves blood glucose levels and affects how the immune system works, and makes it less effective, Adalja said.

“This is why patients with diabetes are at risk for many infections not just coronavirus,” Adalja said. “They often struggle with infections on their skin and soft tissues, with pneumonia and even more serious conditions.”

Those in the high risk group need to be extremely careful.

“If they do become infected, the threshold for them seeking medical attention needs to be much lower. They and their clinicians have to keep this in mind,” Adalja said. “These numbers show us just how crucial that is.”

Wilbur Chen, an infectious-disease physician at the University of Maryland, added that while the virus seems to prey on the elderly and sick, “it does not mean it does not cause severe illness in younger adults or in children — in other words, the risk is not zero among the young.”

He said, “We are now documenting a large number of covid-19 infections across the U.S. and we are now observing more and more of these ‘rare’ events of severe illness and even deaths among the young.”

HOW D’OXYVA CAN HELP?

D’OXYVA works to prevent sepsis, and resulting septic shock, using life-restoring molecule carbon dioxide (CO₂) and gentle vapor dissolved across the skin in a fast, painless, handheld  5-minute application — performed either in a clinical setting or in the comfort and privacy of your own home.

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Check coronavirus symptoms online, thanks to new site

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

Emory University’s Office of Critical Event Preparedness executive director Dr. Alex Isakov and Emory University’s Department of Emergency Medicine chair Dr. David Wright discuss Emory University’s newest development of a site where people who think they may have coronavirus can check to see if their symptoms align with the virus.

Share this:

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

HOW D’OXYVA CAN HELP?

Circularity is already in Phase 3 human clinical trials with most of the top ten U.S. university research institutions with D’OXYVA for FDA approval for rapidly treating chronic conditions such as diabetic wounds and hypertension, and fighting against COVID-19 with an already FDA-approved simple, non-toxic, and widely used molecule in nearly all hospitals around the world.

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

99% of Those Who Died From Virus Had Other Illness, Italy Says

corona virus

More than 99% of Italy’s coronavirus fatalities were people who suffered from previous medical conditions, according to a study by the country’s national health authority.

After deaths from the virus reached more than 2,500, with a 150% increase in the past week, health authorities have been combing through data to provide clues to help combat the spread of the disease.

Share this:

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Prime Minister Giuseppe Conte’s government is evaluating whether to extend a nationwide lockdown beyond the beginning of April, daily La Stampa reported Wednesday. Italy has more than 31,500 confirmed cases of the illness.

 

Italy Coronavirus Deaths

By prior illnesses (%)

Source: ISS Italy National Health Institute, March 17 sample

 

The new study could provide insight into why Italy’s death rate, at about 8% of total infected people, is higher than in other countries.

The Rome-based institute has examined medical records of about 18% of the country’s coronavirus fatalities, finding that just three victims, or 0.8% of the total, had no previous pathology. Almost half of the victims suffered from at least three prior illnesses and about a fourth had either one or two previous conditions.

 

Threat to the Elderly

The median age of the infected is 63 but most of those who die are older
The average age of those who’ve died from the virus in Italy is 79.5. As of March 17, 17 people under 50 had died from the disease. All of Italy’s victims under 40 have been males with serious existing medical conditions.

While data released Tuesday point to a slowdown in the increase of cases, with a 12.6% rise, a separate study shows Italy could be underestimating the real number of cases by testing only patients presenting symptoms.

According to the GIMBE Foundation, about 100,000 Italians have contracted the virus, daily Il Sole 24 Ore reported. That would bring back the country’s death rate closer to the global average of about 2%.

Threat to the Elderly

HOW D’OXYVA CAN HELP?

Circularity is already in Phase 3 human clinical trials with most of the top ten U.S. university research institutions with D’OXYVA for FDA approval for rapidly treating chronic conditions such as diabetic wounds and hypertension, and fighting against COVID-19 with an already FDA-approved simple, non-toxic, and widely used molecule in nearly all hospitals around the world.

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Reduce unwanted doctor visits, recommended and ranked top by experts!